Latest Commercialisation News

Page 1 of 239
Sparc Technologies has appointed former Micro-X chief executive Kingsley Hall to lead its graphene additives and green hydrogen businesses into their next commercial phase. The transition gives Hall an immediate mandate to grow ecosparc sales and advance Sparc Hydrogen beyond pilot operations, while his incentive package ties part of his reward to shareholder returns and revenue milestones.
Sophie Babbage
Sophie Babbage
19 Nov 2026
Temas Resources has secured an estimated C$52,876 Stage 1 contract to test its Regenerative Chloride Leach technology on samples from an unnamed Québec mineral company. The nearby project could offer a regional processing opportunity, while a new governance appointment reshapes the board.
Victor Sage
Victor Sage
19 Nov 2026
FortifAI has appointed former NVIDIA and Elastic sales leader Jason Brushe as CEO, putting commercial partnerships at the centre of NOL8’s next phase. His package includes US$300,000 in annual remuneration and performance rights tied to agreements, partnerships and bookings milestones.
Sophie Babbage
Sophie Babbage
19 Nov 2026
Lark Distilling reported 15.1% FY26 sales growth and entered FY27 debt-free, but shareholders delivered a sharp rebuke on executive pay and director fees. The company now has to turn its new production platform, Signature range and international push into positive operating cash flow.
Victor Sage
Victor Sage
19 Nov 2026
CurveBeam AI has received its first Chinese order for four HiRise weight-bearing CT systems from Weiying/Wego Orthopedics, turning regulatory clearance into an initial commercial foothold. The order value and delivery schedule were not disclosed, while a further A$1 million milestone investment is expected this quarter.
Victor Sage
Victor Sage
19 Nov 2026
Knosys is asking shareholders for up to $4.3 million to move its Libero library software from product development into a staged US commercial launch. The non-underwritten raising will fund a lean local team, anchor customers, procurement access and the planned March 2027 release of Libero 7.
Sophie Babbage
Sophie Babbage
18 Nov 2026
Papyrus has secured acceptance for the first product in its biodegradable Collar Keeper range, opening the door to commercial supply with TBS Mining Solutions. The milestone covers 25% of the contract’s minimum volumes, but production readiness, funding and further product testing remain decisive.
Victor Sage
Victor Sage
18 Nov 2026
Vitrafy says it has moved from cryopreservation research into commercial execution, with 19 Guardion devices built, new US partnerships and $38.3 million in cash and term deposits. The next test is converting partner evaluations into recurring revenue after a planned FDA Class II listing in the coming weeks.
Victor Sage
Victor Sage
17 Nov 2026
Urbanise has entered FY27 with stronger revenue, a near break-even adjusted EBITDA result and a live NAB banking pilot, but the next phase depends on turning contracted work and new platform features into recurring revenue and cash flow. The corrected AGM materials set a target for a positive operating cash flow run rate in the first half of FY28.
Sophie Babbage
Sophie Babbage
17 Nov 2026
ReNerve has converted Indian regulatory approval into its first commercial NervAlign Nerve Cuff procedure, with a Bangalore patient treated for an upper-extremity nerve repair. The milestone arrives after record quarterly sales of $584,000 and expands the company’s Asia-Pacific rollout.
Victor Sage
Victor Sage
17 Nov 2026
Epiminder has signed a five-year rolling partnership with Stratus Neuro to integrate its long-term Minder EEG data into StratusEEG, a cloud platform used by more than 7,000 US clinicians and administrators. The agreement gives Epiminder an established clinical workflow for its DETECT study and planned US commercialisation, although no financial terms or launch date were disclosed.
Victor Sage
Victor Sage
17 Nov 2026
Environmental Clean Technologies has completed its acquisition of Xenica Materials, bringing exclusive production rights and defence and commercial licences for its MXene platform under ECT’s control. The deal issued 60 million shares, while Xenica’s founders agreed to lock up 21 million of them for two years.
Victor Sage
Victor Sage
16 Nov 2026

Browse the archive

Full archive